Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JST-018 combination of 3 monoclonal antibodies · 1 trial · 1 indication
Incidence of solicited local (injection site) and systemic AEs post-injection through Day 7 (with the inpatient and outpatient participant diaries being collected on Day 3 and Day 8, respectively)
Incidence of unsolicited AEs through end of study (EOS)
Incidence of Clinically Significant Changes in Vital Sign Measurements
| Arm | Type | Description |
|---|---|---|
| JST-018 Investigational Product | ACTIVE_COMPARATOR | - |
| JST-017 Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| JST-018 combination of 3 monoclonal antibodies | BIOLOGICAL | Monoclonal antibodies |
| Placebo | DRUG | Placebo Comparator |
Inclusion Criteria: 1. Healthy men or women 18 to 55 years of age 2. BMI between 18 and 32 kg/m2 3. Negative serum pregnancy test 4. Use of highly effective birth control method(s) for a minimum of 60 days prior to consent and is willing to continue use for at least 12 months, or abstinence 5. In g...
JST-018 is an investigational antiviral drug being developed for the treatment of infectious diseases. It is a combination of 3 monoclonal antibodies and is currently in Phase 1 clinical development. The drug is being studied for its safety, tolerability, and pharmacokinetics in healthy adults.
JST-018 is a combination of 3 monoclonal antibodies designed to target viral pathogens. As an antiviral drug, it is intended to neutralize or inhibit viruses that cause infectious diseases. The specific molecular targets of the antibodies have not been disclosed.
JST-018 is being developed by Evotec SE, a biopharmaceutical company listed on the stock exchange under the ticker symbol EVO. The company is conducting a Phase 1 clinical trial to evaluate the drug's safety and tolerability in healthy volunteers.
JST-018 is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to assess the safety, tolerability, and pharmacokinetics of the drug.
JST-018 is being evaluated in a Phase 1 clinical trial with the identifier NCT07595458. This randomized, double-blind, placebo-controlled study is recruiting 48 healthy adults in the United States. The trial aims to assess the safety, tolerability, and pharmacokinetics of JST-018.
JST-018 is a unique combination of 3 monoclonal antibodies and is not known to be the same as any other marketed drug. It is an investigational antiviral agent currently in early-stage clinical development, and no alternative names have been reported.